This downturn is different.
Youssef Sebban interview by Carol Massar and Tim Stenovec on Bloomberg Businessweek.
Listen NowAcuity
Eckuity InsightsInsights, news, commentary and interviews about the life sciences, healthcare and tech world.
Covering life science innovation, market analysis and investment strategy.
){kind=icon}
){kind=icon}
News and updates
May 2023
Where is Big Pharma placing its bets? The upcoming ~$200B patent cliff and the stormy market conditions have significantly increased the pressure on Big Pharma to sustain pipelines while controlling costs. Most of the industry majors slashed their R&D budgets in 2022.
More insights and news
We believe that the “impending” recession is counterbalanced with strong economic data and once we start to peel the layers, we see a slightly different picture.
Read the Whitepaper
Investing In Early-Stage Healthcare Companies
Looks at what’s been driving the record investment into healthcare, what to look for and why commercialization is key.
Read Report
The Future of Wearable Healthtech.
Reviews the innovation drivers and the dramatic growth potential of this very significant market.
Read the Report
First broadcast April 22, 2022
AGELESS THERAPEUTICS
Improving protein therapeutics through anti-glycation modification.
Watch the podcast
Where is Big Pharma placing its bets? The upcoming ~$200B patent cliff and the stormy market conditions have significantly increased the pressure on Big Pharma to sustain pipelines while controlling costs. Most of the industry majors slashed their R&D budgets in 2022.
Read Report
The era of investing in unproven bets is gone, for the foreseeable future, and only the truly innovative and commercially minded will survive.
Read the article
The Future of Wearable HealthTech
Reviews the innovation drivers and the dramatic growth potential of this very significant market.
Read Report
The “impending” recession is counterbalanced with strong economic data and once we start to peel the layers a different picture emerges.
Read the Article
Investing in a promising early-stage healthcare company.
Commercialization is key.
Read the article.
Alléger les coûts de la bioproduction
Reducing the costs of biologic manufacturing. (In french)
Read the article.
Bloomberg Businessweek. Carol Massar and Tim Stenovec interview Youssef Sebban. May 31, 2022
Listen to the interview.